With the socio-economic development and lifestyle changes, the population of chronic diseases associated with lifestyle is also expanding. In the last 30 years, the prevalence of diabetes in China has increased significantly. The results of the 2008 epidemiological survey showed that the prevalence of diabetes in Chinese adults was 9.7%, and the total number of adults with diabetes has reached 92.4 million, thus making China the world’s number one country with diabetes. The classic UKPDS and DCCT trials have confirmed that intensive glycemic therapy can bring long-term benefits in terms of reduced incidence of chronic comorbidities, and that early selection of effective interventions is key to achieving good glycemic control and long-term benefits. The latest 2010 edition of China’s T2DM prevention and treatment guidelines point out that when patients have been treated with a combination of two oral hypoglycemic agents, but their blood glucose still does not meet the standard, insulin therapy should be started early to stabilize blood glucose, and premixed insulin is one of the main choices. Pre-mixed insulin is to take advantage of the difference in the onset of action of different forms of insulin, and mix mealtime insulin to lower postprandial blood sugar and basal insulin to lower fasting blood sugar in a certain proportion, so as to produce dual-phase insulin that can lower both postprandial blood sugar and fasting blood sugar, which can achieve the therapeutic effect of “killing two birds with one stone”, and also reduce the number of daily injections and increase the therapeutic effect of patients. It also reduces the number of injections per day and increases the compliance of treatment. At present, the main forms of premixed insulin available in China are premixed human insulin 30R and 50R, as well as premixed insulin analogues (Novolac 30, Novolac 50, Ural 25 and Ural 50). Premixed human insulin is a mixture of short-acting insulin and intermediate-acting insulin in a certain ratio, and patients only need to inject it twice a day, which is the simplest and most commonly used insulin treatment regimen at present. It is estimated that about 40% of diabetic patients worldwide use premixed human insulin. At present, the commonly used dosage forms in China are premixed human insulin 30R and 50R (such as Eugenol 70/30, Novolin 30R, Rehmannia 30R, Gansulin 30R and Novolin 50R). The short-acting insulin in premixed insulin exists in the form of hexamer, and after injecting it subcutaneously, it must be deconjugated into monomeric small molecules through the continuous dilution and depolymerization of body fluids before it can enter the bloodstream through the tiny pores on the capillary membrane, therefore, it must be injected subcutaneously 30 minutes before mealtime in order to synchronize with the peak time of blood glucose after a person eats. Due to the limitations of conventional human insulin in use, which cannot truly mimic physiological insulin secretion, scientists have developed new insulin dosage forms-insulin analogs. Insulin analogs are the amino acid sequences of human insulin that are altered accordingly, thus changing its onset and duration of action. Premixed human insulin analogs mix fast-acting insulin analogs lyspro or menadione (Aspart) with fast-acting insulin analogs bound to fisetin in a certain ratio. Lispro is to swap the position of proline at position 28 and lysine at position 29 on the chain of human insulin B. Aspart is to replace the proline at position 28 of human insulin B by menthol, while the other amino acid sequence and structure remain unchanged, thus forming a new peptide chain. After the amino acid sequence is changed, the function of insulin does not change, but the insulin which was easy to form dimer and hexamer is no longer easy to gather into dimer and hexamer, but exists in the form of monomer, so that it is easily absorbed after subcutaneous injection and thus works rapidly. At present, the commonly used premixed insulin analogue dosage forms in China are NovoRel 30, NovoRel 50, UroLEL 25 and UroLel 50.